TABLE 3.
Signaling pathways activated/inhibited significantly in response to Alk4 down-regulation using the OncoFinder method
| Name | State | P |
|---|---|---|
| GSK3 pathway (gene expression via CTNNB1) | Activated | 9.34E–07 |
| GSK3 pathway (b-CTNN degradation) | Activated | 1.02E–05 |
| JAK mStat Pathway (JAK degradation) | Inhibited | 1.02E–05 |
| Ubiquitin proteasome–dependent proteolysis pathway | Activated | 4.00E–05 |
| WNT pathway (cell fate proliferation, differentiation, adhesion and survival) | Unclear | 4.77E–05 |
| CD40 pathway | Activated | 2.17E–04 |
| TNF main pathway | Activated | 2.51E–04 |
| p38 pathway (translation) | Unclear | 3.27E–04 |
| IL-2 pathway (IL-2 gene expression) | Activated | 5.14E–04 |
| SMAD signaling network pathway | Unclear | 7.27E–04 |
| GSK3 pathway (glycogen synthesis) | Inhibited | 1.04E–03 |
| mTOR main pathway | Activated | 1.42E–03 |
| WNT main pathway | Unclear | 1.47E–03 |
| PTEN pathway (apoptosis) | Inhibited | 2.00E–03 |
| GSK3 pathway (protein synthesis) | Inhibited | 2.41E–03 |
| TNF pathway (gene expression and cell survival) | Activated | 2.41E–03 |
| AKT main pathway | Activated | 2.48E–03 |
| IL-2 main pathway | Activated | 2.88E–03 |
| IGF1R pathway (glycogen synthesis) | Inhibited | 3.91E–03 |
GSK3, glycogen synthase kinase 3; IGF1R, insulin growth factor- 1 receptor; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog; SMAD, mothers against decapentaplegic homolog 3 Wnt, wingless-type MMTV integration site family.